Title **SmartVax - active adverse event surveillance – 1 million vaccines later !!! – what have we learned ?**

**Author and affiliations**

Dr Alan Leeb - SmartVax

**Background and Aims**

Developed following the 2010 Fluvax disaster, SmartVax actively monitors adverse events following immunisation in real time.

SmartVax was presented at GP14 and was awarded the Peter Mudge medal.

Currently AusVaxSafety, supported by Dept of Health and powered by SmartVax, provides almost all post immunisation adverse event data surveillance for Australia.

GP 18 provides an opportunity to update progress and highlight exciting developments.

**Method**

The SmartVax platform utilises data extracted from practice management software for active surveillance of adverse events following immunisation (AEFI) using SMS and Smartphone technology.

Initially a single site in 2011, the network has grown to over 220 sites including GP, hospital immunisation clinics and local government immunisation clinics.

SmartVax records events for all vaccines at all ages, and includes all scheduled NIP vaccines, influenza vaccines as well as travel and private vaccines.

Non identifiable data is uploaded to a secured central server for data aggregation and analysis.

**Results**

The SmartVax database contains records of over 650,000 immunisation encounters of vaccines delivered in Australia across all ages.

The database, approaching 1 million vaccine antigens, with a response rate of 75%, the overall reaction rate is 7.01% and medical attendance rate following an adverse event is 0.54%.

The database contains –

Adolescent vaccines (including Gardasil) 60,000 (7.9%)

Adult NIP vaccines (including Zostavax and Pneumovax) 31,000 (4.1%)

Influenza (all ages and brands) 120,000 (15.9%)

Childhood NIP schedule vaccines 420,000 (55.9%)

Travel vaccines (including all meningitis vaccines) 120,000 (15.9%)

Further analysis is ongoing, specifically the safety of co- administration of vaccines and the longitudinal safety of repeated vaccines over time.

**Conclusion**

The ongoing safety of the Australian immunisation program is paramount.

SmartVax continues to make significant contributions to local and international vaccine safety data with numerous publications and reports.

The platform is providing a spring board to many exciting and innovative projects.